Cargando…

Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experiments

Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of MICHA (Mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanoli, Ziaurrehman, Aldahdooh, Jehad, Alam, Farhan, Wang, Yinyin, Seemab, Umair, Fratelli, Maddalena, Pavlis, Petr, Hajduch, Marian, Bietrix, Florence, Gribbon, Philip, Zaliani, Andrea, Hall, Matthew D., Shen, Min, Brimacombe, Kyle, Kulesskiy, Evgeny, Saarela, Jani, Wennerberg, Krister, Vähä-Koskela, Markus, Tang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724669/
https://www.ncbi.nlm.nih.gov/pubmed/33300000
http://dx.doi.org/10.1101/2020.12.03.409409
Descripción
Sumario:Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of MICHA (Minimal Information for Chemosensitivity Assays), accessed via https://micha-protocol.org. Distinguished from existing efforts that are often lacking support from data integration tools, MICHA can automatically extract publicly available information to facilitate the assay annotation including: 1) compounds, 2) samples, 3) reagents, and 4) data processing methods. For example, MICHA provides an integrative web server and database to obtain compound annotation including chemical structures, targets, and disease indications. In addition, the annotation of cell line samples, assay protocols and literature references can be greatly eased by retrieving manually curated catalogues. Once the annotation is complete, MICHA can export a report that conforms to the FAIR principle (Findable, Accessible, Interoperable and Reusable) of drug screening studies. To consolidate the utility of MICHA, we provide FAIRified protocols from five major cancer drug screening studies, as well as six recently conducted COVID-19 studies. With the MICHA webserver and database, we envisage a wider adoption of a community-driven effort to improve the open access of drug sensitivity assays.